{"title":"关于附加药物治疗精神分裂症阴性症状有效性的局部研究的系统综述:一项荟萃分析","authors":"S. Shafti","doi":"10.2174/2211556008666190405143828","DOIUrl":null,"url":null,"abstract":"\n\nWhile negative symptoms are connected with poor functioning\nand quality of life, pharmacological managements have imperfect effects on deficit syndrome\nand may even subsidize or aggravate secondary negative symptoms. Meanwhile,\nmanagement of negative symptoms by means of add-on medications has resulted in instable\nconsequences.\n\n\n\nIn the current tryout, some of the indigenous systematic issued studies have\nbeen the theme of a new meta-analysis, to assess the effectiveness of adjunctive psychotropic\ndrugs on deficit syndrome of schizophrenia.\n\n\n\nTwelve randomized placebo-control trials (n=433), which had been implemented\nin Razi psychiatric hospital in the last 14 years, had been selected for the present analysis.\nAs a shared protocol, all cases had been selected amongst the male inpatients, who were\nhospitalized in chronic section of the hospice and had been diagnosed schizophrenia in line\nwith “Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision”.\nIn this regard, the aforesaid samples had been entered into matching-group, double-blind\nassessments for random assignment to a psychotropic medication (like antidepressant, benzodiazepine,\npsycho-stimulant, Acetyl-cholinesterase inhibitors) or placebo in addition to\ntheir current drug. In these trials, “Scale for Assessment of Negative Symptoms (SANS)”\nhad been used as the main outcome measure for evaluation of negative symptoms. Also,\nresponse was defined as a decrease in >20% in the severity of SANS score (over-all and/or\nsub-scales).\n\n\n\nWhile the heterogeneity of the present meta-analysis was intermediate, the “Combined\nEffect Size” of the aforesaid assessments has revealed a significant influence respecting\nefficiency of psychotropic drugs on negative symptoms of schizophrenia (OR =\n5.40, CI=2.69- 10.85, z= 5.32, p<0.000). Similar results, as well, could be found in connection\nwith various negative symptoms. In this regard, ‘Anhedonia-Asociality’ showed the\nbest “Combined Effect Size”, afterwards “Affective Blunting”, “Avolitio -Apathy”, “Attention\nDeficit”, and last of all “Alogia”. “Heterogeneity” of all said analysis was insignificant\nand therefore appropriate.\n\n\n\n According to the findings, psychotropic drugs, as add-on medications, have\nvaluable influence in regard to amelioration of negative symptoms of schizophrenia.\n","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic Review of Local Studies Regarding Efficiency of Add-On Medications on Negative Symptoms of Schizophrenia: A Meta-Analysis\",\"authors\":\"S. Shafti\",\"doi\":\"10.2174/2211556008666190405143828\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nWhile negative symptoms are connected with poor functioning\\nand quality of life, pharmacological managements have imperfect effects on deficit syndrome\\nand may even subsidize or aggravate secondary negative symptoms. Meanwhile,\\nmanagement of negative symptoms by means of add-on medications has resulted in instable\\nconsequences.\\n\\n\\n\\nIn the current tryout, some of the indigenous systematic issued studies have\\nbeen the theme of a new meta-analysis, to assess the effectiveness of adjunctive psychotropic\\ndrugs on deficit syndrome of schizophrenia.\\n\\n\\n\\nTwelve randomized placebo-control trials (n=433), which had been implemented\\nin Razi psychiatric hospital in the last 14 years, had been selected for the present analysis.\\nAs a shared protocol, all cases had been selected amongst the male inpatients, who were\\nhospitalized in chronic section of the hospice and had been diagnosed schizophrenia in line\\nwith “Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision”.\\nIn this regard, the aforesaid samples had been entered into matching-group, double-blind\\nassessments for random assignment to a psychotropic medication (like antidepressant, benzodiazepine,\\npsycho-stimulant, Acetyl-cholinesterase inhibitors) or placebo in addition to\\ntheir current drug. In these trials, “Scale for Assessment of Negative Symptoms (SANS)”\\nhad been used as the main outcome measure for evaluation of negative symptoms. Also,\\nresponse was defined as a decrease in >20% in the severity of SANS score (over-all and/or\\nsub-scales).\\n\\n\\n\\nWhile the heterogeneity of the present meta-analysis was intermediate, the “Combined\\nEffect Size” of the aforesaid assessments has revealed a significant influence respecting\\nefficiency of psychotropic drugs on negative symptoms of schizophrenia (OR =\\n5.40, CI=2.69- 10.85, z= 5.32, p<0.000). Similar results, as well, could be found in connection\\nwith various negative symptoms. In this regard, ‘Anhedonia-Asociality’ showed the\\nbest “Combined Effect Size”, afterwards “Affective Blunting”, “Avolitio -Apathy”, “Attention\\nDeficit”, and last of all “Alogia”. “Heterogeneity” of all said analysis was insignificant\\nand therefore appropriate.\\n\\n\\n\\n According to the findings, psychotropic drugs, as add-on medications, have\\nvaluable influence in regard to amelioration of negative symptoms of schizophrenia.\\n\",\"PeriodicalId\":10751,\"journal\":{\"name\":\"Current Psychopharmacology\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Psychopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2211556008666190405143828\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2211556008666190405143828","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Systematic Review of Local Studies Regarding Efficiency of Add-On Medications on Negative Symptoms of Schizophrenia: A Meta-Analysis
While negative symptoms are connected with poor functioning
and quality of life, pharmacological managements have imperfect effects on deficit syndrome
and may even subsidize or aggravate secondary negative symptoms. Meanwhile,
management of negative symptoms by means of add-on medications has resulted in instable
consequences.
In the current tryout, some of the indigenous systematic issued studies have
been the theme of a new meta-analysis, to assess the effectiveness of adjunctive psychotropic
drugs on deficit syndrome of schizophrenia.
Twelve randomized placebo-control trials (n=433), which had been implemented
in Razi psychiatric hospital in the last 14 years, had been selected for the present analysis.
As a shared protocol, all cases had been selected amongst the male inpatients, who were
hospitalized in chronic section of the hospice and had been diagnosed schizophrenia in line
with “Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision”.
In this regard, the aforesaid samples had been entered into matching-group, double-blind
assessments for random assignment to a psychotropic medication (like antidepressant, benzodiazepine,
psycho-stimulant, Acetyl-cholinesterase inhibitors) or placebo in addition to
their current drug. In these trials, “Scale for Assessment of Negative Symptoms (SANS)”
had been used as the main outcome measure for evaluation of negative symptoms. Also,
response was defined as a decrease in >20% in the severity of SANS score (over-all and/or
sub-scales).
While the heterogeneity of the present meta-analysis was intermediate, the “Combined
Effect Size” of the aforesaid assessments has revealed a significant influence respecting
efficiency of psychotropic drugs on negative symptoms of schizophrenia (OR =
5.40, CI=2.69- 10.85, z= 5.32, p<0.000). Similar results, as well, could be found in connection
with various negative symptoms. In this regard, ‘Anhedonia-Asociality’ showed the
best “Combined Effect Size”, afterwards “Affective Blunting”, “Avolitio -Apathy”, “Attention
Deficit”, and last of all “Alogia”. “Heterogeneity” of all said analysis was insignificant
and therefore appropriate.
According to the findings, psychotropic drugs, as add-on medications, have
valuable influence in regard to amelioration of negative symptoms of schizophrenia.